Key Developments: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

107.86USD
21 Nov 2014
Price Change (% chg)

$0.38 (+0.35%)
Prev Close
$108.18
Open
$108.63
Day's High
$108.65
Day's Low
$107.62
Volume
3,290,952
Avg. Vol
2,240,719
52-wk High
$109.49
52-wk Low
$86.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson announces completion of Alios BioPharma acquisition
Friday, 7 Nov 2014 04:05pm EST 

Johnson & Johnson:Announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of about $1.75 billion in cash.With this acquisition complete, Alios BioPharma will now become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.Acquisition includes Alios BioPharma's portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.  Full Article

Johnson & Johnson announces quarterly dividend for Q4 2014
Thursday, 16 Oct 2014 07:44am EDT 

Johnson & Johnson:Says Board has declared a cash dividend for the Q4 2014 of $0.70 per share on its common stock.Says dividend is payable on Dec. 9, to shareholders of record at the close of business on Nov. 25.  Full Article

Johnson & Johnson raises FY 2014 earnings guidance
Tuesday, 14 Oct 2014 07:45am EDT 

Johnson & Johnson:Increased FY 2014 earnings guidance to $5.92 - $5.97 per share.Says guidance excludes the impact of special items.FY 2014 EPS of $5.93 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson announces agreement to acquire Alios BioPharma
Tuesday, 30 Sep 2014 08:30am EDT 

Johnson & Johnson:Announces definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for about $1.75 billion in cash.The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.The transaction is expected to close during the fourth quarter of 2014.  Full Article

Johnson & Johnson announces $5 bln share repurchase program
Monday, 21 Jul 2014 05:00pm EDT 

Johnson & Johnson:Approves the repurchase of up to $5 billion of the company's common stock.Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.  Full Article

Johnson & Johnson announces quarterly dividend for third quarter 2014
Monday, 21 Jul 2014 11:10am EDT 

Johnson & Johnson:Declares cash dividend for third quarter of 2014 of $0.70 per share on the company's common stock.Dividend is payable on Sept. 09, 2014 to shareholders of record at the close of business on Aug. 26, 2014.Ex-dividend date is Aug. 22, 2014.  Full Article

Johnson & Johnson raises FY 2014 earnings guidance
Tuesday, 15 Jul 2014 07:45am EDT 

Johnson & Johnson:Increased FY 2014 earnings guidance to $5.85 - $5.92 per share.Says guidance excludes the impact of special items.FY 2014 EPS of $5.90 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson completes divestiture of Ortho-Clinical Diagnostics To The Carlyle Group
Monday, 30 Jun 2014 04:30pm EDT 

Johnson & Johnson:Completes divestiture of Ortho-Clinical Diagnostics business to Carlyle Group for about $4 bln, subject to customary adjustments.Under terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, global provider of solutions for screening, diagnosing, monitoring and confirming diseases.  Full Article

Johnson & Johnson announces dividend increase of 6.1 pct
Thursday, 24 Apr 2014 10:22am EDT 

Johnson & Johnson:Declared a 6.1 pct increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share.Payable on June 10 to shareholders of record at the close of business on May 27.Ex-dividend date is May 22.  Full Article

Johnson & Johnson raises FY 2014 guidance - conference Call
Tuesday, 15 Apr 2014 08:30am EDT 

Johnson & Johnson:Expects FY 2014 sales growth to range between 4.5 pct and 5.5 pct for a total expected level of reported sales between $74.5 billion to $75.3 billion, which is higher than previous guidance.Expects FY 2014 EPS, excluding special items, in the range between $5.80 and $5.90 per share or a growth rate of between 5 pct and 7 pct.This is higher than previous guidance.FY 2014 revenue of $74.3 million and EPS of $5.83 - Thomson Reuters I/B/E/S.  Full Article

RPT-J&J seeks over $5 bln in damages from Boston Scientific at trial

NEW YORK, Nov 19 - Nearly a decade after losing a bidding war for device maker Guidant to Boston Scientific Corp , Johnson & Johnson finally has a chance for payback at a multibillion-dollar trial set to begin on Thursday.

Search Stocks